首页 > 最新文献

Journal of Clinical Pathology最新文献

英文 中文
Medium-term storage of frozen residual antenatal sera in gel separator tube is suitable for subsequent serological investigation of intrauterine infection. 将冷冻的产前血清残留物放入凝胶分离管中进行中期储存,适用于随后的宫内感染血清学调查。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-10-20 DOI: 10.1136/jcp-2024-209387
Weiling Ng, Ter Yong Tan, Xin Yu Venessa Chow, Siew Hoon Lim, Wei Yee Wan

Aim: We assessed the feasibility of storing sera in primary gel separator tube over medium-term for retrospective serological tests to facilitate investigation of intra-uterine infection.

Method: 120 residual serum samples, consisting of 30 positive samples each for rubella, cytomegalovirus, parvovirus B19 and varicella zoster IgG were aliquoted into secondary propylene tubes and stored together with the original primary tubes at -20°C for 1 year. The serum was subsequently retested to compare results from both storage methods.

Results: Haemolysis was observed in 49.2% of serum stored in the primary tubes. However, there was no difference in both the qualitative and quantitative results after storage of serum samples in either receptacle.

Conclusion: Sera can be stored in primary blood tube for up to 1 year without affecting serological results. For laboratories with adequate freezer space to store samples in primary blood tubes, this would streamline workflow saving manpower and time, avoid mislabelling of aliquots, reduce consumable costs and prevent unnecessary biohazard exposures.

目的:我们评估了将血清储存在一级凝胶分离管中进行中期回顾性血清学检测的可行性,以便于调查宫内感染:将 120 份残留血清样本(包括风疹、巨细胞病毒、细小病毒 B19 和水痘带状疱疹 IgG 阳性样本各 30 份)等分到二级丙烯管中,与原一级管一起在 -20°C 下保存 1 年。随后重新检测血清,比较两种储存方法的结果:结果:在原试管中储存的血清中有 49.2% 出现溶血。然而,在两种容器中储存血清样本后,定性和定量结果均无差异:结论:血清可在原采血管中储存长达 1 年而不影响血清学结果。对于有足够冷冻空间的实验室来说,将样本储存在原装血管中可简化工作流程,节省人力和时间,避免等分样品贴错标签,降低耗材成本,并防止不必要的生物危害暴露。
{"title":"Medium-term storage of frozen residual antenatal sera in gel separator tube is suitable for subsequent serological investigation of intrauterine infection.","authors":"Weiling Ng, Ter Yong Tan, Xin Yu Venessa Chow, Siew Hoon Lim, Wei Yee Wan","doi":"10.1136/jcp-2024-209387","DOIUrl":"10.1136/jcp-2024-209387","url":null,"abstract":"<p><strong>Aim: </strong>We assessed the feasibility of storing sera in primary gel separator tube over medium-term for retrospective serological tests to facilitate investigation of intra-uterine infection.</p><p><strong>Method: </strong>120 residual serum samples, consisting of 30 positive samples each for rubella, cytomegalovirus, parvovirus B19 and varicella zoster IgG were aliquoted into secondary propylene tubes and stored together with the original primary tubes at -20°C for 1 year. The serum was subsequently retested to compare results from both storage methods.</p><p><strong>Results: </strong>Haemolysis was observed in 49.2% of serum stored in the primary tubes. However, there was no difference in both the qualitative and quantitative results after storage of serum samples in either receptacle.</p><p><strong>Conclusion: </strong>Sera can be stored in primary blood tube for up to 1 year without affecting serological results. For laboratories with adequate freezer space to store samples in primary blood tubes, this would streamline workflow saving manpower and time, avoid mislabelling of aliquots, reduce consumable costs and prevent unnecessary biohazard exposures.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"779-782"},"PeriodicalIF":2.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. 免疫组化法对 pan-Trk 的核染色对分泌型乳腺癌具有高度特异性:pan-Trk 在各种亚型乳腺癌中的应用。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-10-20 DOI: 10.1136/jcp-2023-208989
Qiqi Ye, Hui Chen, Cody Han, Yan Peng, Xiao Huang, Hongxia Sun, Yun Wu, Constance T Albarracin, Lavinia P Middleton, Aysegul A Sahin, Lei Huo, Qingqing Ding

Aims: Secretory carcinoma of breast (SCB) typically harbours ETV6-NTRK3 gene fusion. Pan-Trk immunohistochemistry analysis (IHC) has been shown to be sensitive for SCB diagnosis. However, weak focal pan-Trk nuclear staining was previously found in 10% of non-secretory breast carcinomas. To further examine pan-Trk IHC specificity, we evaluated pan-Trk staining in various breast carcinoma subtypes.

Methods: The study cohort consisted of 346 invasive breast carcinomas (IBCs), including 8 SCBs and 48 triple-negative histological mimickers (36 metaplastic carcinomas, including 12 matrix-producing carcinomas; 5 adenoid cystic carcinomas; 5 apocrine carcinomas; 2 acinic cell carcinomas), 101 triple-negative IBCs of no special type, 101 estrogen receptor (ER)-positive/HER2-negative IBCs and 88 HER2-positive IBCs. Six salivary gland secretory carcinomas were also included. Pan-Trk IHC was performed on tumours using a rabbit monoclonal pan-Trk antibody. Any nuclear staining in the invasive carcinoma cells was considered positive.

Results: All 14 secretory carcinomas from breast and salivary gland exhibited moderate to strong pan-Trk nuclear staining. In contrast, no pan-Trk nuclear staining was identified in any of the 338 non-secretory IBCs. Focal cytoplasmic pan-Trk staining was observed in nine non-secretory IBCs (2.7%), and was considered nonspecific and negative.

Conclusions: Our results indicate that pan-Trk nuclear staining is highly specific for SCB. In low-grade to intermediate-grade IBCs that share histological features with SCB, adding pan-Trk to a routing panel of estrogen receptor/progesterone receptor/HER2 is highly diagnostic. Our results also support using pan-Trk IHC to differentiate SCB from its triple-negative histological mimickers, such as adenoid cystic carcinoma, matrix-producing carcinoma, apocrine carcinoma and acinic cell carcinoma.

目的:乳腺分泌性癌(SCB)通常携带 ETV6-NTRK3 基因融合。泛Trk免疫组化分析(IHC)已被证明对SCB诊断敏感。然而,以前曾在10%的非分泌型乳腺癌中发现弱局灶性pan-Trk核染色。为了进一步研究泛Trk IHC的特异性,我们评估了各种乳腺癌亚型的泛Trk染色情况:研究队列包括 346 例浸润性乳腺癌(IBC),其中包括 8 例 SCB 和 48 例三阴性组织学模拟者(36 例移行细胞癌,其中包括 12 例基质生成癌、5 例腺样囊性癌、5 例腺样囊性癌、5 例腺样囊性癌、5 例腺样囊性癌、5 例腺样囊性癌、5 例腺样囊性癌、5 例腺样囊性癌);5个腺样囊性癌;5个分泌性癌;2个尖细胞癌)、101个无特殊类型的三阴性IBC、101个雌激素受体(ER)阳性/HER2阴性IBC和88个HER2阳性IBC。其中还包括 6 例唾液腺分泌性癌。使用兔单克隆 pan-Trk 抗体对肿瘤进行 Pan-Trk IHC 检测。浸润癌细胞中的任何核染色均被视为阳性:结果:来自乳腺和唾液腺的所有 14 例分泌性癌均表现出中等至较强的泛 Trk 核染色。相比之下,在 338 个非分泌型 IBC 中均未发现泛 Trk 核染色。在9个非分泌型IBC(2.7%)中观察到局部胞浆pan-Trk染色,被认为是非特异性和阴性的:我们的研究结果表明,pan-Trk核染色对SCB具有高度特异性。对于与SCB具有相同组织学特征的中低分级IBC,将pan-Trk加入雌激素受体/孕激素受体/HER2的路由面板中具有很高的诊断价值。我们的研究结果还支持使用pan-Trk IHC将SCB与其三阴性组织学模拟者(如腺样囊性癌、基质生成癌、无泌乳素癌和尖细胞癌)区分开来。
{"title":"Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma.","authors":"Qiqi Ye, Hui Chen, Cody Han, Yan Peng, Xiao Huang, Hongxia Sun, Yun Wu, Constance T Albarracin, Lavinia P Middleton, Aysegul A Sahin, Lei Huo, Qingqing Ding","doi":"10.1136/jcp-2023-208989","DOIUrl":"10.1136/jcp-2023-208989","url":null,"abstract":"<p><strong>Aims: </strong>Secretory carcinoma of breast (SCB) typically harbours <i>ETV6-NTRK3</i> gene fusion. Pan-Trk immunohistochemistry analysis (IHC) has been shown to be sensitive for SCB diagnosis. However, weak focal pan-Trk nuclear staining was previously found in 10% of non-secretory breast carcinomas. To further examine pan-Trk IHC specificity, we evaluated pan-Trk staining in various breast carcinoma subtypes.</p><p><strong>Methods: </strong>The study cohort consisted of 346 invasive breast carcinomas (IBCs), including 8 SCBs and 48 triple-negative histological mimickers (36 metaplastic carcinomas, including 12 matrix-producing carcinomas; 5 adenoid cystic carcinomas; 5 apocrine carcinomas; 2 acinic cell carcinomas), 101 triple-negative IBCs of no special type, 101 estrogen receptor (ER)-positive/HER2-negative IBCs and 88 HER2-positive IBCs. Six salivary gland secretory carcinomas were also included. Pan-Trk IHC was performed on tumours using a rabbit monoclonal pan-Trk antibody. Any nuclear staining in the invasive carcinoma cells was considered positive.</p><p><strong>Results: </strong>All 14 secretory carcinomas from breast and salivary gland exhibited moderate to strong pan-Trk nuclear staining. In contrast, no pan-Trk nuclear staining was identified in any of the 338 non-secretory IBCs. Focal cytoplasmic pan-Trk staining was observed in nine non-secretory IBCs (2.7%), and was considered nonspecific and negative.</p><p><strong>Conclusions: </strong>Our results indicate that pan-Trk nuclear staining is highly specific for SCB. In low-grade to intermediate-grade IBCs that share histological features with SCB, adding pan-Trk to a routing panel of estrogen receptor/progesterone receptor/HER2 is highly diagnostic. Our results also support using pan-Trk IHC to differentiate SCB from its triple-negative histological mimickers, such as adenoid cystic carcinoma, matrix-producing carcinoma, apocrine carcinoma and acinic cell carcinoma.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"751-755"},"PeriodicalIF":2.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10389327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of algorithmic cytomorphological assessment and immunocytochemistry with the international system for reporting serous fluid cytopathology on pericardial fluid cytology. 将国际浆液细胞病理学报告系统的细胞形态学评估和免疫细胞化学算法应用于心包积液细胞学检查。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-10-20 DOI: 10.1136/jcp-2023-209078
Joshua J X Li, Wing Cheung, Joanna K M Ng, Gary M Tse

Aims: The international system for reporting serous fluid cytopathology (ISRSFC) set forth a five-tiered reporting system with comprehensive validation on pleural and peritoneal fluid cytology. An algorithmic approach for cytomorphological assessment and immunocytochemistry was also described in ISRSFC. Limited data on pericardial fluid are supportive but would benefit from further investigation.

Methods: Consecutive pericardial fluid cytology over a 4-year period was reviewed by multiple board-certified pathologists according to the ISRSFC. Cytomorphology and immunocytochemistry were assessed sequentially, with respective diagnostic performances computed and compared. Literature review was performed.

Results: In total 358 specimens, including 53 with immunocytochemistry available, were reviewed. There were 137 benign and 221 malignant (MAL) cases. The risks of malignancy were 23.5% non-diagnostic (ND), 29.2% negative for malignancy (NFM), 56.0% atypia of undetermined significance (AUS), 82.6% suspicious for malignancy (SFM) and 99.2% (MAL) for cytomorphological assessment, improving to 23.5% (ND), 29.1% (NFM), 56.8% (AUS), 78.9% (SFM) and 99.3% (MAL) incorporating immunocytochemistry. Ten cases (2.8%) received a change in diagnosis after review of immunocytochemistry. All revisions of diagnostic category were appropriate upgrades/downgrades referenced against clinical information. Cytomorphological typing was accurate for adenocarcinoma (n=81/83, 97.6%), while other carcinomas and lymphomas required immunocytochemistry. Certain subcategories within AUS and SFM pertaining to bland indeterminate epithelial cells or mucinous material were not seen for pericardial fluid.

Conclusions: The ISRSFC shows robust diagnostic performance for pericardial fluid cytology. For pericardial effusion, disease composition and applicable cytological subcategories differ from its peritoneal and pleural counterparts. Incorporating immunocytochemistry by an algorithmic approach improves diagnostic accuracy. Cytomorphology is accurate for identifying adenocarcinomas, but further typing necessitates immunocytochemistry is necessary.

目的:国际浆液细胞病理学报告系统(ISRSFC)建立了一个五级报告系统,并对胸膜和腹腔积液细胞学进行了全面验证。ISRSFC 中还描述了细胞形态学评估和免疫细胞化学的算法方法。有关心包积液的数据有限,但仍需进一步研究:方法:多位经委员会认证的病理学家根据 ISRSFC 对 4 年内连续的心包积液细胞学进行了审查。依次对细胞形态学和免疫细胞化学进行评估,计算并比较各自的诊断结果。还进行了文献综述:结果:共审查了 358 份标本,包括 53 份免疫细胞化学标本。良性病例 137 例,恶性病例(MAL)221 例。细胞形态学评估的恶性风险分别为:23.5%未诊断(ND)、29.2%恶性阴性(NFM)、56.0%意义未定的不典型性(AUS)、82.6%恶性可疑(SFM)和99.2%(MAL),免疫细胞化学评估的恶性风险分别为:23.5%(ND)、29.1%(NFM)、56.8%(AUS)、78.9%(SFM)和99.3%(MAL)。有 10 个病例(2.8%)在免疫细胞化学检查后改变了诊断。所有诊断类别的修订都是根据临床信息进行的适当升级/降级。细胞形态学分型对腺癌(n=81/83,97.6%)是准确的,而其他癌和淋巴瘤则需要免疫细胞化学检查。AUS和SFM中与平滑不确定上皮细胞或粘液性物质有关的某些亚类在心包积液中未见:结论:ISRSFC 对心包积液细胞学检查具有很强的诊断能力。心包积液的疾病构成和适用的细胞学亚类与腹膜和胸膜积液不同。通过算法方法结合免疫细胞化学可提高诊断准确性。细胞形态学可准确鉴别腺癌,但进一步分型需要免疫细胞化学。
{"title":"Application of algorithmic cytomorphological assessment and immunocytochemistry with the international system for reporting serous fluid cytopathology on pericardial fluid cytology.","authors":"Joshua J X Li, Wing Cheung, Joanna K M Ng, Gary M Tse","doi":"10.1136/jcp-2023-209078","DOIUrl":"10.1136/jcp-2023-209078","url":null,"abstract":"<p><strong>Aims: </strong>The international system for reporting serous fluid cytopathology (ISRSFC) set forth a five-tiered reporting system with comprehensive validation on pleural and peritoneal fluid cytology. An algorithmic approach for cytomorphological assessment and immunocytochemistry was also described in ISRSFC. Limited data on pericardial fluid are supportive but would benefit from further investigation.</p><p><strong>Methods: </strong>Consecutive pericardial fluid cytology over a 4-year period was reviewed by multiple board-certified pathologists according to the ISRSFC. Cytomorphology and immunocytochemistry were assessed sequentially, with respective diagnostic performances computed and compared. Literature review was performed.</p><p><strong>Results: </strong>In total 358 specimens, including 53 with immunocytochemistry available, were reviewed. There were 137 benign and 221 malignant (MAL) cases. The risks of malignancy were 23.5% non-diagnostic (ND), 29.2% negative for malignancy (NFM), 56.0% atypia of undetermined significance (AUS), 82.6% suspicious for malignancy (SFM) and 99.2% (MAL) for cytomorphological assessment, improving to 23.5% (ND), 29.1% (NFM), 56.8% (AUS), 78.9% (SFM) and 99.3% (MAL) incorporating immunocytochemistry. Ten cases (2.8%) received a change in diagnosis after review of immunocytochemistry. All revisions of diagnostic category were appropriate upgrades/downgrades referenced against clinical information. Cytomorphological typing was accurate for adenocarcinoma (n=81/83, 97.6%), while other carcinomas and lymphomas required immunocytochemistry. Certain subcategories within AUS and SFM pertaining to bland indeterminate epithelial cells or mucinous material were not seen for pericardial fluid.</p><p><strong>Conclusions: </strong>The ISRSFC shows robust diagnostic performance for pericardial fluid cytology. For pericardial effusion, disease composition and applicable cytological subcategories differ from its peritoneal and pleural counterparts. Incorporating immunocytochemistry by an algorithmic approach improves diagnostic accuracy. Cytomorphology is accurate for identifying adenocarcinomas, but further typing necessitates immunocytochemistry is necessary.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"766-771"},"PeriodicalIF":2.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10485896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms. 用人工智能算法评估早期非小细胞肺癌的 PD-L1 表达和肿瘤浸润淋巴细胞。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-10-17 DOI: 10.1136/jcp-2024-209766
Aida Molero, Susana Hernandez, Marta Alonso, Melina Peressini, Daniel Curto, Fernando Lopez-Rios, Esther Conde

Aims: To study programmed death ligand 1 (PD-L1) expression and tumour infiltrating lymphocytes (TILs) in patients with early-stage non-small cell lung carcinoma (NSCLC) with artificial intelligence (AI) algorithms.

Methods: The study included samples from 50 early-stage NSCLCs. PD-L1 immunohistochemistry (IHC) stained slides (clone SP263) were scored manually and with two different AI tools (PathAI and Navify Digital Pathology) by three pathologists. TILs were digitally assessed on H&E and CD8 IHC stained sections with two different algorithms (PathAI and Navify Digital Pathology, respectively). The agreement between observers and methods for each biomarker was analysed. For PD-L1, the turn-around time (TAT) for manual versus AI-assisted scoring was recorded.

Results: Agreement was higher in tumours with low PD-L1 expression regardless of the approach. Both AI-powered tools identified a significantly higher number of cases equal or above 1% PD-L1 tumour proportion score as compared with manual scoring (p=0.00015), a finding with potential therapeutic implications. Regarding TAT, there were significant differences between manual scoring and AI use (p value <0.0001 for all comparisons). The total TILs density with the PathAI algorithm and the total density of CD8+ cells with the Navify Digital Pathology software were significantly correlated (τ=0.49 (95% CI 0.37, 0.61), p value<0.0001).

Conclusions: This preliminary study supports the use of AI algorithms for the scoring of PD-L1 and TILs in patients with NSCLC.

目的:利用人工智能(AI)算法研究早期非小细胞肺癌(NSCLC)患者的程序性死亡配体1(PD-L1)表达和肿瘤浸润淋巴细胞(TILs):研究包括50例早期NSCLC样本。PD-L1免疫组化(IHC)染色切片(克隆SP263)由三位病理学家通过人工和两种不同的人工智能工具(PathAI和Navify Digital Pathology)进行评分。用两种不同的算法(分别是 PathAI 和 Navify Digital Pathology)对 H&E 和 CD8 IHC 染色切片上的 TIL 进行数字评估。对每种生物标记物的观察者和方法之间的一致性进行了分析。对于 PD-L1,记录了人工与 AI 辅助评分的周转时间(TAT):结果:无论采用哪种方法,PD-L1 低表达肿瘤的一致性都较高。与人工评分相比(P=0.00015),两种人工智能辅助工具识别出的等于或高于1% PD-L1肿瘤比例评分的病例数量都显著增加,这一发现具有潜在的治疗意义。在 TAT 方面,人工评分与使用人工智能之间存在显著差异(P 值 结论:人工智能在肿瘤治疗中的应用具有潜在的治疗意义:这项初步研究支持使用人工智能算法对 NSCLC 患者的 PD-L1 和 TIL 进行评分。
{"title":"Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms.","authors":"Aida Molero, Susana Hernandez, Marta Alonso, Melina Peressini, Daniel Curto, Fernando Lopez-Rios, Esther Conde","doi":"10.1136/jcp-2024-209766","DOIUrl":"https://doi.org/10.1136/jcp-2024-209766","url":null,"abstract":"<p><strong>Aims: </strong>To study programmed death ligand 1 (PD-L1) expression and tumour infiltrating lymphocytes (TILs) in patients with early-stage non-small cell lung carcinoma (NSCLC) with artificial intelligence (AI) algorithms.</p><p><strong>Methods: </strong>The study included samples from 50 early-stage NSCLCs. PD-L1 immunohistochemistry (IHC) stained slides (clone SP263) were scored manually and with two different AI tools (PathAI and Navify Digital Pathology) by three pathologists. TILs were digitally assessed on H&E and CD8 IHC stained sections with two different algorithms (PathAI and Navify Digital Pathology, respectively). The agreement between observers and methods for each biomarker was analysed. For PD-L1, the turn-around time (TAT) for manual versus AI-assisted scoring was recorded.</p><p><strong>Results: </strong>Agreement was higher in tumours with low PD-L1 expression regardless of the approach. Both AI-powered tools identified a significantly higher number of cases equal or above 1% PD-L1 tumour proportion score as compared with manual scoring (p=0.00015), a finding with potential therapeutic implications. Regarding TAT, there were significant differences between manual scoring and AI use (p value <0.0001 for all comparisons). The total TILs density with the PathAI algorithm and the total density of CD8+ cells with the Navify Digital Pathology software were significantly correlated (τ=0.49 (95% CI 0.37, 0.61), p value<0.0001).</p><p><strong>Conclusions: </strong>This preliminary study supports the use of AI algorithms for the scoring of PD-L1 and TILs in patients with NSCLC.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic literature review of published cases of reactive plasmacytosis in peripheral blood and bone marrow. 关于外周血和骨髓中反应性浆细胞增多症已发表病例的系统文献综述。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-10-04 DOI: 10.1136/jcp-2024-209513
Margarita Munoz de Toro, Sebastian Fernandez-Pol

Aims: This study aims to summarise published cases of reactive plasmacytosis to provide a resource to aid haematopathologists and clinicians in the diagnostic workup of reactive plasmacytosis.

Methods: We searched published articles on reactive plasmacytosis on PubMed, Scopus and Google Scholar. Data were screened following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Cases were classified into six categories, namely: (1) infection, (2) angioimmunoblastic T-cell lymphoma (AITL), (3) other malignancies, (4) drug associated, (5) autoimmune diseases and (6) others. Plasma cell percentage in peripheral blood and/or bone marrow was tabulated. Descriptive statistics were reported as median with IQR, using JASP Team.

Results: 87 articles which reported on 146 patients were included. Infectious diseases represented most cases associated with reactive plasmacytosis (n=46, 31% of all cases), with viral infections being the most frequent (n=31, 21% of all cases). AITL was the second most frequent aetiology (n=34, 23% of all cases), followed by medications (n=28, 19% of all cases), other malignancies (n=18, 12% of all cases), miscellaneous aetiologies (n=11, 7% of all cases) and autoimmune diseases (n=9, 6% of all cases). The absolute and relative levels of plasma cells in each diagnostic category showed marked variation and ranges largely overlapped between categories.

Conclusions: In patients with an increase in the number and/or proportion of plasma cells in peripheral blood and/or bone marrow, clinical context and a broad differential diagnosis are necessary to direct further evaluation and arrive at a correct diagnosis. Our literature review suggests that evaluation for infectious causes and AITL may be of the greatest yield in many cases.

目的:本研究旨在总结已发表的反应性浆细胞增多症病例,为血液病理学家和临床医生诊断反应性浆细胞增多症提供帮助:我们在 PubMed、Scopus 和 Google Scholar 上检索了有关反应性浆细胞增多症的已发表文章。数据筛选遵循《2020 年系统综述和荟萃分析首选报告项目》指南。病例分为六类,即:(1) 感染;(2) 血管免疫母细胞性 T 细胞淋巴瘤(AITL);(3) 其他恶性肿瘤;(4) 药物相关;(5) 自身免疫性疾病;(6) 其他。外周血和/或骨髓中浆细胞的百分比以表格形式列出。使用 JASP 团队以中位数和 IQR 的形式报告描述性统计:结果:共纳入 87 篇文章,报告了 146 名患者的情况。感染性疾病是与反应性浆细胞增多症相关的大多数病例(n=46,占所有病例的31%),其中病毒感染最为常见(n=31,占所有病例的21%)。AITL是第二位最常见的病因(n=34,占所有病例的23%),其次是药物(n=28,占所有病例的19%)、其他恶性肿瘤(n=18,占所有病例的12%)、其他病因(n=11,占所有病例的7%)和自身免疫性疾病(n=9,占所有病例的6%)。每个诊断类别中浆细胞的绝对水平和相对水平都有明显差异,不同类别之间的范围基本重叠:对于外周血和/或骨髓中浆细胞数量和/或比例增加的患者,临床背景和广泛的鉴别诊断是指导进一步评估和得出正确诊断的必要条件。我们的文献综述表明,在许多病例中,对感染性病因和 AITL 的评估可能是最有效的方法。
{"title":"Systematic literature review of published cases of reactive plasmacytosis in peripheral blood and bone marrow.","authors":"Margarita Munoz de Toro, Sebastian Fernandez-Pol","doi":"10.1136/jcp-2024-209513","DOIUrl":"10.1136/jcp-2024-209513","url":null,"abstract":"<p><strong>Aims: </strong>This study aims to summarise published cases of reactive plasmacytosis to provide a resource to aid haematopathologists and clinicians in the diagnostic workup of reactive plasmacytosis.</p><p><strong>Methods: </strong>We searched published articles on reactive plasmacytosis on PubMed, Scopus and Google Scholar. Data were screened following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Cases were classified into six categories, namely: (1) infection, (2) angioimmunoblastic T-cell lymphoma (AITL), (3) other malignancies, (4) drug associated, (5) autoimmune diseases and (6) others. Plasma cell percentage in peripheral blood and/or bone marrow was tabulated. Descriptive statistics were reported as median with IQR, using JASP Team.</p><p><strong>Results: </strong>87 articles which reported on 146 patients were included. Infectious diseases represented most cases associated with reactive plasmacytosis (n=46, 31% of all cases), with viral infections being the most frequent (n=31, 21% of all cases). AITL was the second most frequent aetiology (n=34, 23% of all cases), followed by medications (n=28, 19% of all cases), other malignancies (n=18, 12% of all cases), miscellaneous aetiologies (n=11, 7% of all cases) and autoimmune diseases (n=9, 6% of all cases). The absolute and relative levels of plasma cells in each diagnostic category showed marked variation and ranges largely overlapped between categories.</p><p><strong>Conclusions: </strong>In patients with an increase in the number and/or proportion of plasma cells in peripheral blood and/or bone marrow, clinical context and a broad differential diagnosis are necessary to direct further evaluation and arrive at a correct diagnosis. Our literature review suggests that evaluation for infectious causes and AITL may be of the greatest yield in many cases.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging fusion-associated mesenchymal tumours: a tabular guide and appraisal of five 'novel' entities. 新出现的融合相关间叶肿瘤:五种 "新型 "实体的表格指南和评估。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-09-20 DOI: 10.1136/jcp-2024-209460
Jinesa Moodley, Ivan Chebib

Aims: The field of molecular pathology has undergone significant advancements in the clinical impact of sarcoma diagnosis, resulting in challenges to nosology of bone and soft tissue tumours. The surge in molecular data has led to the identification of novel fusions and description of new 'entities'. To illustrate this, we have selected five emerging entities with novel fusions: clear cell stromal tumour of the lung with YAP1::TFE3 fusion, GAB1::ABL1 fusion spindle cell neoplasm, NUTM1-rearranged sarcomas, NR1D1-rearranged sarcomas and calcified chondroid mesenchymal neoplasms.

Methods: Literature for the relevant case reports and case series of these five entities were reviewed and clinicopathological data was collected. Additionally, this review includes a table format of recently described fusion-associated mesenchymal neoplasms.

Results: The morphological and immunohistochemical features, along with diagnostic challenges, are discussed for each entity.

Conclusions: Here, we have provided a review of selected emerging mesenchymal neoplasms, which of these neoplasms will meet the threshold to be 'new entities' remains to be determined.

目的:分子病理学领域在肉瘤诊断的临床影响方面取得了重大进展,给骨和软组织肿瘤的命名带来了挑战。分子数据的激增导致了新型融合的发现和新 "实体 "的描述。为了说明这一点,我们选择了五个新出现的新型融合实体:YAP1::TFE3融合的肺透明细胞间质瘤、GAB1::ABL1融合的纺锤形细胞瘤、NUTM1重组肉瘤、NR1D1重组肉瘤和钙化软骨间充质肿瘤:方法:对这五种实体的相关病例报告和系列病例进行了文献综述,并收集了临床病理学数据。此外,本综述还以表格形式列出了最近描述的融合相关间叶肿瘤:结果:讨论了每个实体的形态学和免疫组化特征以及诊断难题:在此,我们对一些新出现的间叶肿瘤进行了综述,但其中哪些肿瘤将达到 "新实体 "的门槛仍有待确定。
{"title":"Emerging fusion-associated mesenchymal tumours: a tabular guide and appraisal of five 'novel' entities.","authors":"Jinesa Moodley, Ivan Chebib","doi":"10.1136/jcp-2024-209460","DOIUrl":"https://doi.org/10.1136/jcp-2024-209460","url":null,"abstract":"<p><strong>Aims: </strong>The field of molecular pathology has undergone significant advancements in the clinical impact of sarcoma diagnosis, resulting in challenges to nosology of bone and soft tissue tumours. The surge in molecular data has led to the identification of novel fusions and description of new 'entities'. To illustrate this, we have selected five emerging entities with novel fusions: clear cell stromal tumour of the lung with <i>YAP1::TFE3</i> fusion, <i>GAB1::ABL1</i> fusion spindle cell neoplasm, <i>NUTM1</i>-rearranged sarcomas, <i>NR1D1</i>-rearranged sarcomas and calcified chondroid mesenchymal neoplasms.</p><p><strong>Methods: </strong>Literature for the relevant case reports and case series of these five entities were reviewed and clinicopathological data was collected. Additionally, this review includes a table format of recently described fusion-associated mesenchymal neoplasms.</p><p><strong>Results: </strong>The morphological and immunohistochemical features, along with diagnostic challenges, are discussed for each entity.</p><p><strong>Conclusions: </strong>Here, we have provided a review of selected emerging mesenchymal neoplasms, which of these neoplasms will meet the threshold to be 'new entities' remains to be determined.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extraction and classification of structured data from unstructured hepatobiliary pathology reports using large language models: a feasibility study compared with rules-based natural language processing. 使用大型语言模型从非结构化肝胆病理报告中提取结构化数据并进行分类:与基于规则的自然语言处理进行比较的可行性研究。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-09-20 DOI: 10.1136/jcp-2024-209669
Ruben Geevarghese, Carlie Sigel, John Cadley, Subrata Chatterjee, Pulkit Jain, Alex Hollingsworth, Avijit Chatterjee, Nathaniel Swinburne, Khawaja Hasan Bilal, Brett Marinelli

Aims: Structured reporting in pathology is not universally adopted and extracting elements essential to research often requires expensive and time-intensive manual curation. The accuracy and feasibility of using large language models (LLMs) to extract essential pathology elements, for cancer research is examined here.

Methods: Retrospective study of patients who underwent pathology sampling for suspected hepatocellular carcinoma and underwent Ytrrium-90 embolisation. Five pathology report elements of interest were included for evaluation. LLMs (Generative Pre-trained Transformer (GPT) 3.5 turbo and GPT-4) were used to extract elements of interest. For comparison, a rules-based, regular expressions (REGEX) approach was devised for extraction. Accuracy for each approach was calculated.

Results: 88 pathology reports were identified. LLMs and REGEX were both able to extract research elements with high accuracy (average 84.1%-94.8%).

Conclusions: LLMs have significant potential to simplify the extraction of research elements from pathology reporting, and therefore, accelerate the pace of cancer research.

目的:病理学中的结构化报告并没有得到普遍采用,提取对研究至关重要的内容往往需要昂贵且耗时的人工整理。本文探讨了使用大型语言模型(LLMs)提取癌症研究必需病理要素的准确性和可行性:方法:对因怀疑患有肝细胞癌而进行病理取样并接受 Ytrrium-90 栓塞术的患者进行回顾性研究。评估包括五项相关病理报告要素。使用 LLM(生成预训练变换器 (GPT) 3.5 turbo 和 GPT-4)提取感兴趣的元素。为了进行比较,还设计了一种基于规则的正则表达式 (REGEX) 方法进行提取。计算了每种方法的准确性:共识别出 88 份病理报告。LLM 和 REGEX 都能以较高的准确率(平均 84.1%-94.8%)提取研究元素:LLMs 在简化病理报告中研究元素的提取方面具有巨大潜力,因此可以加快癌症研究的步伐。
{"title":"Extraction and classification of structured data from unstructured hepatobiliary pathology reports using large language models: a feasibility study compared with rules-based natural language processing.","authors":"Ruben Geevarghese, Carlie Sigel, John Cadley, Subrata Chatterjee, Pulkit Jain, Alex Hollingsworth, Avijit Chatterjee, Nathaniel Swinburne, Khawaja Hasan Bilal, Brett Marinelli","doi":"10.1136/jcp-2024-209669","DOIUrl":"https://doi.org/10.1136/jcp-2024-209669","url":null,"abstract":"<p><strong>Aims: </strong>Structured reporting in pathology is not universally adopted and extracting elements essential to research often requires expensive and time-intensive manual curation. The accuracy and feasibility of using large language models (LLMs) to extract essential pathology elements, for cancer research is examined here.</p><p><strong>Methods: </strong>Retrospective study of patients who underwent pathology sampling for suspected hepatocellular carcinoma and underwent Ytrrium-90 embolisation. Five pathology report elements of interest were included for evaluation. LLMs (Generative Pre-trained Transformer (GPT) 3.5 turbo and GPT-4) were used to extract elements of interest. For comparison, a rules-based, regular expressions (REGEX) approach was devised for extraction. Accuracy for each approach was calculated.</p><p><strong>Results: </strong>88 pathology reports were identified. LLMs and REGEX were both able to extract research elements with high accuracy (average 84.1%-94.8%).</p><p><strong>Conclusions: </strong>LLMs have significant potential to simplify the extraction of research elements from pathology reporting, and therefore, accelerate the pace of cancer research.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumour stemness and poor clinical outcomes in haemochromatosis patients with hepatocellular carcinoma. 血色素沉着病肝细胞癌患者的肿瘤干细胞和不良临床预后。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-09-19 DOI: 10.1136/jcp-2022-208679
Daniel M Di Capua, William Shanahan, Michele Bourke, Navneet Ramlaul, Josh Appel, Aoife Canney, Neil G Docherty, Erinn McGrath, Eabha Ring, Fiona Jones, Marie Boyle, Janet McCormack, Tom Gallagher, Emir Hoti, Niamh Nolan, John D Ryan, Diarmaid D Houlihan, Aurelie Fabre

Aims: Patients with haemochromatosis (HFE) are known to have an increased risk of developing hepatocellular carcinoma (HCC). Available data are conflicting on whether such patients have poorer prognosis, and there is lack of data regarding the biology of HFE-HCC. We compared the course of HFE-HCC with a matched non-HFE-HCC control group and examined tumour characteristics using immunohistochemistry.

Methods: In this tertiary care-based retrospective analysis, 12 patients with HFE and 34 patients with alcohol/non-alcoholic steatohepatitis who underwent initially successful curative HCC therapy with ablation or resection were identified from our registry. Time to tumour progression was compared. Resected liver tissue from a separate cohort of 11 matched patients with HFE-HCC and without HFE-HCC was assessed for the expression of progenitor and epithelial-mesenchymal transition markers using immunohistochemistry.

Results: The median follow-up was 24.39 and 24.28 months for patients with HFE-HCC and those without HFE-HCC, respectively (p>0.05). The mean time to progression was shorter in the HFE group compared with the non-HFE group (12.87 months vs 17.78 months; HR 3.322, p<0.05). Patients with HFE-HCC also progressed to more advanced disease by the end of follow-up (p<0.05). Immunohistochemical analysis of matched HFE-HCC and non-HFE-HCC explants demonstrated increased expression of the cancer stem cell markers EpCAM (epithelial cell adhesion molecule) and EpCAM/SALL4 (spalt-like transcription factor 4) coexpression in HFE-HCC specimens (p<0.05). There was a high frequency of combined tumour subtypes within the HFE cohort.

Conclusions: This study demonstrates that the clinical course of patients with HFE-HCC is more aggressive and provides the first data indicating that their tumours have increased expression of progenitor markers. These findings suggest patients with HFE-HCC may need to be considered for transplant at an earlier stage.

目的:众所周知,血色素沉着病(HFE)患者罹患肝细胞癌(HCC)的风险较高。关于这类患者的预后是否较差,现有数据并不一致,而且缺乏有关 HFE-HCC 生物学方面的数据。我们比较了 HFE-HCC 与匹配的非 HFE-HCC 对照组的病程,并使用免疫组化方法检查了肿瘤特征:在这项以三级医疗机构为基础的回顾性分析中,从我们的登记册中确定了 12 名 HFE 患者和 34 名酒精/非酒精性脂肪性肝炎患者,他们都接受了消融或切除术,初步成功治愈了 HCC。比较了肿瘤进展的时间。我们使用免疫组化方法评估了11名匹配的HFE-HCC患者和非HFE-HCC患者的切除肝组织中祖细胞和上皮-间质转化标记物的表达情况:HFE-HCC患者和非HFE-HCC患者的中位随访时间分别为24.39个月和24.28个月(P>0.05)。与非 HFE 组相比,HFE 组患者的平均病情进展时间更短(12.87 个月 vs 17.78 个月;HR 3.322,p 结论:该研究表明,HFE-HCC 患者的临床病程比非 HFE-HCC 患者更长:这项研究表明,HFE-HCC 患者的临床病程更具侵袭性,并首次提供了表明其肿瘤中祖细胞标记物表达增多的数据。这些发现表明,HFE-HCC 患者可能需要更早地考虑移植。
{"title":"Tumour stemness and poor clinical outcomes in haemochromatosis patients with hepatocellular carcinoma.","authors":"Daniel M Di Capua, William Shanahan, Michele Bourke, Navneet Ramlaul, Josh Appel, Aoife Canney, Neil G Docherty, Erinn McGrath, Eabha Ring, Fiona Jones, Marie Boyle, Janet McCormack, Tom Gallagher, Emir Hoti, Niamh Nolan, John D Ryan, Diarmaid D Houlihan, Aurelie Fabre","doi":"10.1136/jcp-2022-208679","DOIUrl":"10.1136/jcp-2022-208679","url":null,"abstract":"<p><strong>Aims: </strong>Patients with haemochromatosis (HFE) are known to have an increased risk of developing hepatocellular carcinoma (HCC). Available data are conflicting on whether such patients have poorer prognosis, and there is lack of data regarding the biology of HFE-HCC. We compared the course of HFE-HCC with a matched non-HFE-HCC control group and examined tumour characteristics using immunohistochemistry.</p><p><strong>Methods: </strong>In this tertiary care-based retrospective analysis, 12 patients with HFE and 34 patients with alcohol/non-alcoholic steatohepatitis who underwent initially successful curative HCC therapy with ablation or resection were identified from our registry. Time to tumour progression was compared. Resected liver tissue from a separate cohort of 11 matched patients with HFE-HCC and without HFE-HCC was assessed for the expression of progenitor and epithelial-mesenchymal transition markers using immunohistochemistry.</p><p><strong>Results: </strong>The median follow-up was 24.39 and 24.28 months for patients with HFE-HCC and those without HFE-HCC, respectively (p>0.05). The mean time to progression was shorter in the HFE group compared with the non-HFE group (12.87 months vs 17.78 months; HR 3.322, p<0.05). Patients with HFE-HCC also progressed to more advanced disease by the end of follow-up (p<0.05). Immunohistochemical analysis of matched HFE-HCC and non-HFE-HCC explants demonstrated increased expression of the cancer stem cell markers EpCAM (epithelial cell adhesion molecule) and EpCAM/SALL4 (spalt-like transcription factor 4) coexpression in HFE-HCC specimens (p<0.05). There was a high frequency of combined tumour subtypes within the HFE cohort.</p><p><strong>Conclusions: </strong>This study demonstrates that the clinical course of patients with HFE-HCC is more aggressive and provides the first data indicating that their tumours have increased expression of progenitor markers. These findings suggest patients with HFE-HCC may need to be considered for transplant at an earlier stage.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"669-675"},"PeriodicalIF":2.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10239440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calculated LDL-cholesterol: comparability of the extended Martin/Hopkins, Sampson/NIH, Friedewald and four other equations in South African patients. 计算出的低密度脂蛋白胆固醇:在南非病人中,扩展的马丁/霍普金斯、桑普森/美国国立卫生研究院、弗里德瓦尔德和其他四种公式的可比性。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-09-19 DOI: 10.1136/jcp-2023-208916
Amber Carelse, Helgard M Rossouw, Nicolene Steyn, Janine Martins, Tahir S Pillay

Aims: The reference method for low-density lipoprotein-cholesterol (LDL-C) is ultracentrifugation. However, this is unsuitable for routine use and therefore direct LDL-C assays and predictive equations are used. In this study, we compared the Friedewald, extended Martin/Hopkins, Sampson/NIH and four other equations to a direct assay.

Methods: We analysed 44 194 lipid profiles from a mixed South African population. The LDL-C predictive equations were compared with direct LDL-C assay and analysed using non-parametric statistics and error grid analysis.

Results: Both the extended Martin/Hopkins and Sampson/NIH equations displayed the best correlation with direct LDL-C in terms of desirable bias and total allowable error. The direct LDL-C assay classified 13.9% of patients in the low LDL-C (1.0-1.8 mmol/L) category, in comparison to the extended Martin/Hopkins equation (13.4%), the Sampson equation (14.6%) and the Friedewald equation (16.0%). The Sampson/NIH was least biased in the low LDL-C category (<1.8 mmol/L) and produced the least overall clinically relevant errors compared with the extended Martin/Hopkins and Friedewald equations in the low-LDL-C category.

Conclusions: Our findings suggest only a marginal difference between the extended Martin/Hopkins equation and the Sampson/NIH equation with the use of the Beckman Coulter DxC800 analyser in this population. The results favour the implementation of the Sampson/NIH equation when the Beckman Coulter DxC analyser is used, but the extended Martin/Hopkins may also be safely implemented. Both of these equations performed significantly better than the Friedewald equation. We recommend that patients be monitored using one of these methods and that each laboratory perform its own validation of either equation to ensure continuation and accuracy, and to prevent between-method variation.

目的:低密度脂蛋白胆固醇(LDL-C)的参考方法是超速离心法。然而,这种方法不适合常规使用,因此人们使用直接的低密度脂蛋白胆固醇测定法和预测方程。在这项研究中,我们将弗里德瓦尔德、扩展马丁/霍普金斯、桑普森/NIH 和其他四种方程与直接测定法进行了比较:我们分析了来自南非混合人群的 44 194 份血脂图谱。将低密度脂蛋白胆固醇预测方程与直接低密度脂蛋白胆固醇测定法进行了比较,并使用非参数统计和误差网格分析进行了分析:结果:扩展的马丁/霍普金斯方程和桑普森/NIH 方程在理想偏差和总允许误差方面都显示出与直接 LDL-C 的最佳相关性。与扩展马丁/霍普金斯方程(13.4%)、桑普森方程(14.6%)和弗里德瓦尔德方程(16.0%)相比,直接低密度脂蛋白胆固醇测定法将 13.9% 的患者归入低低密度脂蛋白胆固醇(1.0-1.8 mmol/L)类别。在低 LDL-C 类别中,桑普森/NIH 偏差最小(结论:我们的研究结果表明,在这一人群中使用贝克曼库尔特 DxC800 分析仪时,扩展马丁/霍普金斯方程与桑普森/NIH 方程之间的差异微乎其微。使用贝克曼库尔特 DxC 分析仪时,结果倾向于使用桑普森/NIH 方程,但也可以安全地使用扩展马丁/霍普金斯方程。这两个方程的性能都明显优于弗里德瓦尔德方程。我们建议使用其中一种方法对患者进行监测,并建议各实验室自行对任一方程进行验证,以确保其持续性和准确性,并防止方法间的差异。
{"title":"Calculated LDL-cholesterol: comparability of the extended Martin/Hopkins, Sampson/NIH, Friedewald and four other equations in South African patients.","authors":"Amber Carelse, Helgard M Rossouw, Nicolene Steyn, Janine Martins, Tahir S Pillay","doi":"10.1136/jcp-2023-208916","DOIUrl":"10.1136/jcp-2023-208916","url":null,"abstract":"<p><strong>Aims: </strong>The reference method for low-density lipoprotein-cholesterol (LDL-C) is ultracentrifugation. However, this is unsuitable for routine use and therefore direct LDL-C assays and predictive equations are used. In this study, we compared the Friedewald, extended Martin/Hopkins, Sampson/NIH and four other equations to a direct assay.</p><p><strong>Methods: </strong>We analysed 44 194 lipid profiles from a mixed South African population. The LDL-C predictive equations were compared with direct LDL-C assay and analysed using non-parametric statistics and error grid analysis.</p><p><strong>Results: </strong>Both the extended Martin/Hopkins and Sampson/NIH equations displayed the best correlation with direct LDL-C in terms of desirable bias and total allowable error. The direct LDL-C assay classified 13.9% of patients in the low LDL-C (1.0-1.8 mmol/L) category, in comparison to the extended Martin/Hopkins equation (13.4%), the Sampson equation (14.6%) and the Friedewald equation (16.0%). The Sampson/NIH was least biased in the low LDL-C category (<1.8 mmol/L) and produced the least overall clinically relevant errors compared with the extended Martin/Hopkins and Friedewald equations in the low-LDL-C category.</p><p><strong>Conclusions: </strong>Our findings suggest only a marginal difference between the extended Martin/Hopkins equation and the Sampson/NIH equation with the use of the Beckman Coulter DxC800 analyser in this population. The results favour the implementation of the Sampson/NIH equation when the Beckman Coulter DxC analyser is used, but the extended Martin/Hopkins may also be safely implemented. Both of these equations performed significantly better than the Friedewald equation. We recommend that patients be monitored using one of these methods and that each laboratory perform its own validation of either equation to ensure continuation and accuracy, and to prevent between-method variation.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"656-662"},"PeriodicalIF":2.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic implications of the immunohistochemical expression of perilipin 1 and adipophilin in high-grade liposarcoma. 高级脂肪肉瘤中过脂蛋白 1 和嗜脂素的免疫组化表达对预后的影响
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-09-19 DOI: 10.1136/jcp-2023-208814
Kengo Kawaguchi, Kenichi Kohashi, Taro Mori, Hidetaka Yamamoto, Takeshi Iwasaki, Izumi Kinoshita, Yosuke Susuki, Hiroshi Furukawa, Makoto Endo, Yoshihiro Matsumoto, Yasuharu Nakashima, Yoshinao Oda

Aims: Liposarcoma is a malignant soft tissue tumour with adipocytic differentiation. Dedifferentiated liposarcoma (DDLS) and myxoid liposarcoma (MLS) are classified as high-grade liposarcomas. Lipid droplet-associated protein (also known as perilipin 1 (PLIN1)) is the predominant perilipin and has utility as a specific marker of adipogenic differentiation. Adipose differentiation-related protein (also known as adipophilin (ADRP)) is ubiquitously expressed in a range of tissues. High ADRP expression is reportedly a poor prognostic factor in several cancer types. However, no previous studies have examined the association between PLIN1 or ADRP expression and prognosis in sarcoma. This study therefore aimed to evaluate the association between PLIN1 or ADRP expression and prognosis in liposarcoma.

Methods: In total, 97 primary resection specimens (53 MLS and 44 DDLS) were examined in this study. PLIN1 and ADRP expression was evaluated by immunohistochemistry. Survival analyses were performed for MLS and DDLS.

Results: Of the 53 MLS specimens, 15 (28.3%) exhibited high PLIN1 expression. PLIN1 expression was not observed in DDLS specimens. High PLIN1 expression was significantly associated with increased disease-free survival (DFS) among patients with MLS (p=0.045). Distinct ADRP expression was observed in 13 of 53 (24.5%) MLS specimens and 5 of 44 (11.4%) DDLS specimens. High ADRP expression was associated with shorter overall survival (OS) in MLS (p=0.042) and DFS and shorter OS in DDLS (p=0.024 and p<0.001, respectively).

Conclusions: PLIN1 and ADRP expression is associated with poor prognosis in high-grade liposarcoma.

目的:脂肪肉瘤是一种具有脂肪细胞分化的恶性软组织肿瘤。已分化脂肪肉瘤(DDLS)和类肉脂肪肉瘤(MLS)被归类为高级别脂肪肉瘤。脂滴相关蛋白(又称过脂素 1 (PLIN1))是最主要的过脂素,可作为脂肪分化的特异性标志物。脂肪分化相关蛋白(又称嗜脂素(ADRP))在一系列组织中普遍表达。据报道,ADRP 的高表达是几种癌症类型的不良预后因素。然而,以前没有研究探讨过 PLIN1 或 ADRP 表达与肉瘤预后之间的关系。因此,本研究旨在评估脂肪肉瘤中PLIN1或ADRP表达与预后的关系:方法:本研究共检测了 97 例原发切除标本(53 例 MLS 和 44 例 DDLS)。免疫组化法评估了PLIN1和ADRP的表达。对MLS和DDLS进行了生存分析:在 53 例 MLS 标本中,15 例(28.3%)显示 PLIN1 高表达。在DDLS标本中未观察到PLIN1表达。PLIN1的高表达与MLS患者无病生存期(DFS)的延长有明显相关性(P=0.045)。在53例MLS标本中的13例(24.5%)和44例DDLS标本中的5例(11.4%)中观察到了ADRP的不同表达。ADRP的高表达与MLS较短的总生存期(OS)(p=0.042)和DDLS的DFS和较短的OS(p=0.024和p结论:PLIN1和ADRP的表达与高级别脂肪肉瘤的不良预后有关。
{"title":"Prognostic implications of the immunohistochemical expression of perilipin 1 and adipophilin in high-grade liposarcoma.","authors":"Kengo Kawaguchi, Kenichi Kohashi, Taro Mori, Hidetaka Yamamoto, Takeshi Iwasaki, Izumi Kinoshita, Yosuke Susuki, Hiroshi Furukawa, Makoto Endo, Yoshihiro Matsumoto, Yasuharu Nakashima, Yoshinao Oda","doi":"10.1136/jcp-2023-208814","DOIUrl":"10.1136/jcp-2023-208814","url":null,"abstract":"<p><strong>Aims: </strong>Liposarcoma is a malignant soft tissue tumour with adipocytic differentiation. Dedifferentiated liposarcoma (DDLS) and myxoid liposarcoma (MLS) are classified as high-grade liposarcomas. Lipid droplet-associated protein (also known as perilipin 1 (PLIN1)) is the predominant perilipin and has utility as a specific marker of adipogenic differentiation. Adipose differentiation-related protein (also known as adipophilin (ADRP)) is ubiquitously expressed in a range of tissues. High ADRP expression is reportedly a poor prognostic factor in several cancer types. However, no previous studies have examined the association between PLIN1 or ADRP expression and prognosis in sarcoma. This study therefore aimed to evaluate the association between PLIN1 or ADRP expression and prognosis in liposarcoma.</p><p><strong>Methods: </strong>In total, 97 primary resection specimens (53 MLS and 44 DDLS) were examined in this study. PLIN1 and ADRP expression was evaluated by immunohistochemistry. Survival analyses were performed for MLS and DDLS.</p><p><strong>Results: </strong>Of the 53 MLS specimens, 15 (28.3%) exhibited high PLIN1 expression. PLIN1 expression was not observed in DDLS specimens. High PLIN1 expression was significantly associated with increased disease-free survival (DFS) among patients with MLS (p=0.045). Distinct ADRP expression was observed in 13 of 53 (24.5%) MLS specimens and 5 of 44 (11.4%) DDLS specimens. High ADRP expression was associated with shorter overall survival (OS) in MLS (p=0.042) and DFS and shorter OS in DDLS (p=0.024 and p<0.001, respectively).</p><p><strong>Conclusions: </strong>PLIN1 and ADRP expression is associated with poor prognosis in high-grade liposarcoma.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"676-682"},"PeriodicalIF":2.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9557283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1